Larimar Therapeutics, Inc.
LRMR- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001374690
In the last 90 days, Larimar Therapeutics, Inc. insiders filed 7 open-market purchases and 0 sales; 163 institutions reported holding it in 13F filings for Q2 2026, worth $291.4M in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 11, 2026
- $283.6M
- Insider buysLast 90 days, $382.1K in total
- 7
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +3 vs. previous quarter
- 163
- 13F valueReported value at the end of Q2 2026
- $291.4M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- –
- No comparable prior period
- Net income, FY2025
- -$165.7M
- No comparable prior period
- Free cash flow, FY2025
- -$113.3M
- No comparable prior period
- Revenue, Q2 FY2026
- –
- No comparable prior period
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 10.5M
- Shares sold short
- Change
- −4.12M
- −28.1% vs. previous
- Days to cover
- 8.25
- At average daily volume
Superinvestors holding LRMR, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding LRMR at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Larimar Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 12, 2026 (view filing)9:32 PM ET | Nov 12 | Same day | Hamilton Thomas EdwardDirector | PPurchase | +70.0K | $2.67 | +$187.1K | New position70.0K after | |
| Nov 12, 2026 (view filing)6:02 PM ET | Nov 11 | 1 day | Ben-Maimon CarolePresident and CEO | PPurchase | +18.1K | $2.77 | +$50.0K | +4.9%386.3K after | |
| Nov 12, 2026 (view filing)6:01 PM ET | Nov 11 | 1 day | Thomas Frank EDirector | PPurchase | +8.00K | $2.73 | +$21.8K | +114.3%15.0K after | |
| Nov 12, 2026 (view filing)6:00 PM ET | Nov 11 | 1 day | Truitt JosephDirector | PPurchase | +3.50K | $2.80 | +$9.79K | +127.3%6.25K after | |
| Nov 12, 2026 (view filing)6:00 PM ET | Nov 11 | 1 day | Harlow John B. Jr.President and COO | PPurchase | +17.8K | $2.80 | +$49.9K | +35.6%67.8K after | |
| Nov 12, 2026 (view filing)5:56 PM ET | Nov 11 | 1 day | Celano MichaelChief Financial Officer | PPurchase | +18.5K | $2.71 | +$50.0K | +8.6%234.2K after | |
| Nov 12, 2026 (view filing)5:55 PM ET | Nov 11 | 1 day | Shankar GopiChief Development Officer | PPurchase | +5.00K | $2.71 | +$13.5K | +6.5%81.4K after | |
| Jul 8, 2026 (view filing)4:05 PM ET | Jul 6 | 2 days | Hamilton Thomas EdwardDirector | PPurchase | +50.0K | $3.34 | +$166.9K | +7.5%714.8K after | |
| Mar 2, 2026 (view filing)7:46 PM ET | Feb 27 | 3 days | Deerfield Management Company, L.P. and 9 othersDirector, 10% Owner, Other: * Director by Deputization | PPurchase | +5.00M | $5.00 | +$25.0M | +413.9%6.21M after | 4 lots |
| Mar 2, 2026 (view filing) | Feb 27 | 3 days | Hamilton Thomas EdwardDirector | PPurchase | +100.0K | $5.00 | +$500.0K | +17.7%664.8K after |
Top 10 13F holders, Q2 2026
See all 163 holdersThe largest institutional positions in Larimar Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Deerfield Management Company, L.P. (Series C) | 35,606,974 | $108.6M | 1.13% | 00.0% | Unchanged |
| Blue Owl Capital Holdings LP | 9,163,157 | $27.9M | 4.25% | +2,043,150+28.7% | Added |
| BlackRock, Inc. | 5,678,035 | $17.3M | 0.00% | +1,925,835+51.3% | Added |
| Defilade Capital Management, L.P. | 3,670,135 | $11.2M | 1.50% | +3,670,135 | New |
| Driehaus Capital Management LLC | 3,163,423 | $9.65M | 0.06% | +229,024+7.8% | Added |
| Vanguard Capital Management LLC | 2,974,901 | $9.07M | 0.00% | +108,552+3.8% | Added |
| RTW Investments, LP | 2,565,999 | $7.83M | 0.07% | +1,065,999+71.1% | Added |
| AQR Capital Management LLC | 2,371,414 | $7.23M | 0.00% | +1,553,897+190.1% | Added |
| Marshall Wace, LLP | 2,012,458 | $6.14M | 0.01% | +1,078,994+115.6% | Added |
| DAFNA Capital Management LLC | 2,008,164 | $6.12M | 1.17% | −21,000−1.0% | Reduced |
Holders of 5% or more of LRMR
See all 2 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Larimar Therapeutics, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Flynn James E | 13D/A | 34.41%35.7M shares | −1.40 ppfrom 35.81% | May 21, 202110 filings | Mar 2, 2026 | SEC |
| Blue Owl Capital Holdings LP | 13G/A | 9.99%10.7M shares | 0.00 ppfrom 9.99% | Feb 14, 20244 filings | May 14, 2026 | SEC |